Sirolimus + Teclistamab or Talquetamab

Impact of Sirolimus Pre-conditioning on T Cell Activity and T-cell Engaging Bispecific Antibody Efficacy in Multiple Myeloma

More Information

Trial Status
Accepting patients
Trial Phase
Phase 1
Enrollment
10 patients (estimated)
Sponsors
Holden Comprehensive Cancer Center - University of Iowa
Tags
Mammalian Target of Rapamycin (mTOR) Inhibitor, Immunosuppressant, Cytoprotectant
Trial Type
Treatment
Last Update
SparkCures ID
2259
NCT Identifier
NCT07581704

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print a patient-friendly report to share with your patient.

(888) 850-0650

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.